Clinical trial
A Phase II, Multicentric, Prospective, Non-comparative Clinical Trial to Assess the Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency (PDH) Patients With Glycerol Phenybutyrate (RAVICTI®)
NCT06887777 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicentric, Prospective, Non-comparative Clinical Trial to Assess the Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency (PDH) Patients With Glycerol Phenybutyrate (RAVICTI®)
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 1, 2025
- Completion date
- April 1, 2027
- Enrollment
- 15 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.